Teva Ordered Again To Delist Inhaler Patents From The Orange Book. But Is This The End?
The US FTC Celebrated The Decision, Which May Affect Other Combination Products
The fight between Teva and Amneal over the ProAir HFA inhaler has reached another milestone, with the appellate court affirming the previous ruling to delist five patents from the FDA’s Orange Book. However, Teva might not be backing down.
